The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The cost of drug development: A systematic review
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Spending on new drug development1
Adams, C. P., & Brantner, V. V. (2010) · Health Economics · doi:10.1002/hec.1454 · Cited by 277
Mergers and acquisitions in the pharmaceutical and biotech industries
Danzon, P. M., Epstein, A., & Nicholson, S. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1343 · Cited by 236
Returns to R&D on new drug introductions in the 1980s
Grabowski, H. G., & Vernon, J. M. (1994) · Journal of Health Economics · doi:10.1016/0167-6296(94)90010-8 · Cited by 197
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995) · PharmacoEconomics · doi:10.2165/00019053-199507020-00007 · Cited by 169
Issues in Pharmaceutical Economics
Steele, H., & Chien, R. I. (1980) · Southern Economic Journal · doi:10.2307/1057285 · Cited by 120
Cited by
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
3D bioactive composite scaffolds for bone tissue engineering
Turnbull, G., Clarke, J., Picard, F., Riches, P., Jia, L., Han, F., Li, B., & Shu, W. (2018) · Bioactive Materials · doi:10.1016/j.bioactmat.2017.10.001 · Cited by 1,332
Machine Learning Methods in Drug Discovery
Patel, L., Shukla, T., Huang, X., Ussery, D. W., & Wang, S. (2020) · Molecules · doi:10.3390/molecules25225277 · Cited by 460
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Key cost drivers of pharmaceutical clinical trials in the United States
Sertkaya, A., Wong, H.-H., Jessup, A., & Beleche, T. (2016) · Clinical Trials · doi:10.1177/1740774515625964 · Cited by 401
Metadata
- Authors
- Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D.
- Venue
- Health Policy
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 100
- Issue
- 1
- Pages
- 4-17
- ISSN
- 0168-8510 (ISSN-L)
- OpenAlex
- W1970577443
- Cited by
- 510
- References
- 14
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cost of drug development: A systematic review. https://app.cochat.ai/papers/10.1016/j.healthpol.2010.12.002
- The paper
- Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D. (2011). The cost of drug development: A systematic review. Health Policy. https://doi.org/10.1016/j.healthpol.2010.12.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.